Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
Hepatoprotective peptides operate through bioregulation. Short amino acid chains bind to DNA regulatory regions in hepatocytes and modulate transcription of inflammatory genes. This isn't supplementation in the traditional sense;…
BPC-157 VEGF/FGF-2 upregulation → angiogenesis and fibroblast migration to injury zone 250–500 mcg daily SC for 8–12 weeks Animal tendon models only; no human RCTs for labral tears Begin week 2–3 post-injury; pair with progressiv…
Thymalin (thymic peptide) T-cell modulation; cytokine suppression 10mg IM twice weekly × 10 weeks St. Petersburg Institute: 33% ALT reduction, 41% CRP reduction 8–10 weeks Strongest human trial data; best for inflammatory liver d…
GH Secretagogues (MK-677, Hexarelin, CJC-1295/Ipamorelin) Stimulate pituitary GH release via ghrelin receptor or GHRH analog pathways Restore pulsatile GH secretion suppressed by estrogen withdrawal; improve lean mass, bone densi…
BPC-157 VEGF receptor activation; angiogenesis; collagen type I synthesis Inflammatory and proliferative (days 1–21) 200–300mcg daily Peri-injury IM or subQ abdominal Best first-line option for grade 1–2 strains; acts fastest in …
BPC-157 eNOS stabilisation, microvascular protection 10–100 μg/kg daily × 7 days Multiple animal models, no human RCTs Within 24 hours of injury Strongest evidence for acute ischemia-reperfusion injury; timing-dependent Thymosin …
BPC-157 Nitric oxide pathway modulation; promotes smooth muscle relaxation and mucosal healing 250–500mcg per dose, 1–2× daily Subcutaneous or oral Preclinical rodent models strong; human case series limited, no RCTs Most studied…
BPC-157 Nitric oxide modulation, VEGF signaling, mucosal healing Gastric motility normalisation, reduces delayed emptying and gas accumulation Preclinical only. 40+ animal studies, limited human case reports 200–500mcg daily subc…
Fermented dairy (IPP/VPP) Isoleucine-proline-proline, valine-proline-proline 3–5g peptides in 150–200ml product Competitive ACE inhibition (IC50 5–9 μM) 4–7 mmHg systolic after 8–12 weeks Most clinically validated approach. Consi…
| Peptide | Proposed Mechanism | Strongest Published Evidence | LDL-C Reduction (Mean %) | Triglyceride Reduction (Mean %) | Adjunctive Use Case | Bottom Line ||—|—|—|—|—|—|| Thymosin Alpha-1 | T-cell immune modulation, reduced o…
Proton-Pump Inhibitors (PPIs) Inhibit H+/K+-ATPase pumps, reducing gastric acid secretion by 80–95% Symptom relief in 2–5 days; mucosal healing in 4–8 weeks High. Multiple Phase III trials, FDA-approved for erosive esophagitis Go…
BPC-157 VEGF upregulation, cytokine suppression, angiogenesis 200–500 mcg daily subcutaneous Subcutaneous injection near affected region Moderate. Rodent models show consistent anti-inflammatory effects; human data limited to cas…
Semaglutide (Ozempic, Wegovy) GLP-1 receptor agonist. Slows gastric emptying, reduces insulin secretion Meta-analysis: 18–24% reduction in fasting insulin, 31% improvement in ovulation (2024 JCEM) 0.5–1.0mg weekly (PCOS trials); …
BPC-157 Modulates VEGF, nitric oxide, and pro-inflammatory cytokines (IL-6, TNF-α); promotes angiogenesis in healing tissue while inhibiting pathological neovascularisation In vitro models + 1 exploratory human pilot (n=18, open-…
Before selecting a peptide for research or therapeutic exploration, understanding the evidence quality, mechanism specificity, and practical administration requirements is essential. This comparison evaluates the three most-studi…
Every peptide protocol carries distinct mechanisms, evidence levels, and administration requirements. The table below compares the three most-referenced peptides in chronic pain research. BPC-157 Modulates substance P; enhances V…
| Peptide | Mechanism | Evidence Level | Optimal Phase | Typical Research Concentration | Consumer Product Concentration | Professional Assessment ||—|—|—|—|—|—|| GHK-Cu | TGF-β1 downregulation, MMP-2 upregulation | Phase II clin…
| Peptide | Mechanism of Action | Strongest Evidence Base | Administration Route | Dosing Protocol (Published) | ADHD-Specific Data | Professional Assessment ||—|—|—|—|—|—|| Cerebrolysin | BDNF/NGF upregulation, NMDA modulation |…
LL-37 Peptide (1.5%) Membrane disruption + immune modulation 6–8 weeks Minimal. Transient stinging in 12% of users Phase III RCT (n=214) Best-tolerated antimicrobial option for inflammatory acne; comparable efficacy to retinoids …
BPC-157 VEGF upregulation, mucosal repair, tight junction stabilization 250–500mcg daily Subcutaneous or oral 4–6 weeks Best evidence for direct mucosal healing. Targets barrier integrity at the cellular level KPV NF-κB inhibitio…